Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

Sean P. David, Raymond Niaura, George D. Papandonatos, William G. Shadel, Gary J. Burkholder, Dana M. Britt, Amy Day, Jeffrey Stumpff, Kent Hutchison, Michael Murphy, Elaine Johnstone, Siân Elin Griffiths, Robert T. Walton

Research output: Contribution to journalArticle

Abstract

Bupropion hydrochloride is effective in promoting long-term abstinence from smoking and may reduce risk for relapse through attenuation of withdrawal symptoms and craving. Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies. Thirty smokers were randomly assigned to bupropion or placebo and interviewed using the Minnesota Nicotine Withdrawal Scale on two occasions: prior to starting medication and after 14 days on bupropion or placebo. The individual symptoms of craving, irritability, and anxiety were significantly reduced in the bupropion group, whereas no withdrawal symptoms were diminished in the placebo group. Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. In the DRD2-Taq1 A1/A1 and A1/A2 groups, no significant reduction was seen in any individual symptom of the nicotine withdrawal syndrome. These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor.

Original languageEnglish (US)
Pages (from-to)935-942
Number of pages8
JournalNicotine and Tobacco Research
Volume5
Issue number6
DOIs
StatePublished - Dec 2003

Fingerprint

Bupropion
Nicotine
Substance Withdrawal Syndrome
varespladib methyl
Dopamine D2 Receptors
Genotype
Placebos
Therapeutics
Anxiety
Dopamine Uptake Inhibitors
Tobacco Use Disorder
Case-Control Studies
Smoking
Recurrence

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? / David, Sean P.; Niaura, Raymond; Papandonatos, George D.; Shadel, William G.; Burkholder, Gary J.; Britt, Dana M.; Day, Amy; Stumpff, Jeffrey; Hutchison, Kent; Murphy, Michael; Johnstone, Elaine; Griffiths, Siân Elin; Walton, Robert T.

In: Nicotine and Tobacco Research, Vol. 5, No. 6, 12.2003, p. 935-942.

Research output: Contribution to journalArticle

David, SP, Niaura, R, Papandonatos, GD, Shadel, WG, Burkholder, GJ, Britt, DM, Day, A, Stumpff, J, Hutchison, K, Murphy, M, Johnstone, E, Griffiths, SE & Walton, RT 2003, 'Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?', Nicotine and Tobacco Research, vol. 5, no. 6, pp. 935-942. https://doi.org/10.1080/14622200310001615295
David, Sean P. ; Niaura, Raymond ; Papandonatos, George D. ; Shadel, William G. ; Burkholder, Gary J. ; Britt, Dana M. ; Day, Amy ; Stumpff, Jeffrey ; Hutchison, Kent ; Murphy, Michael ; Johnstone, Elaine ; Griffiths, Siân Elin ; Walton, Robert T. / Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?. In: Nicotine and Tobacco Research. 2003 ; Vol. 5, No. 6. pp. 935-942.
@article{2fca024c74bc49a1983c15ad0d0b6558,
title = "Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?",
abstract = "Bupropion hydrochloride is effective in promoting long-term abstinence from smoking and may reduce risk for relapse through attenuation of withdrawal symptoms and craving. Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies. Thirty smokers were randomly assigned to bupropion or placebo and interviewed using the Minnesota Nicotine Withdrawal Scale on two occasions: prior to starting medication and after 14 days on bupropion or placebo. The individual symptoms of craving, irritability, and anxiety were significantly reduced in the bupropion group, whereas no withdrawal symptoms were diminished in the placebo group. Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. In the DRD2-Taq1 A1/A1 and A1/A2 groups, no significant reduction was seen in any individual symptom of the nicotine withdrawal syndrome. These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor.",
author = "David, {Sean P.} and Raymond Niaura and Papandonatos, {George D.} and Shadel, {William G.} and Burkholder, {Gary J.} and Britt, {Dana M.} and Amy Day and Jeffrey Stumpff and Kent Hutchison and Michael Murphy and Elaine Johnstone and Griffiths, {Si{\^a}n Elin} and Walton, {Robert T.}",
year = "2003",
month = "12",
doi = "10.1080/14622200310001615295",
language = "English (US)",
volume = "5",
pages = "935--942",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

AU - David, Sean P.

AU - Niaura, Raymond

AU - Papandonatos, George D.

AU - Shadel, William G.

AU - Burkholder, Gary J.

AU - Britt, Dana M.

AU - Day, Amy

AU - Stumpff, Jeffrey

AU - Hutchison, Kent

AU - Murphy, Michael

AU - Johnstone, Elaine

AU - Griffiths, Siân Elin

AU - Walton, Robert T.

PY - 2003/12

Y1 - 2003/12

N2 - Bupropion hydrochloride is effective in promoting long-term abstinence from smoking and may reduce risk for relapse through attenuation of withdrawal symptoms and craving. Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies. Thirty smokers were randomly assigned to bupropion or placebo and interviewed using the Minnesota Nicotine Withdrawal Scale on two occasions: prior to starting medication and after 14 days on bupropion or placebo. The individual symptoms of craving, irritability, and anxiety were significantly reduced in the bupropion group, whereas no withdrawal symptoms were diminished in the placebo group. Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. In the DRD2-Taq1 A1/A1 and A1/A2 groups, no significant reduction was seen in any individual symptom of the nicotine withdrawal syndrome. These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor.

AB - Bupropion hydrochloride is effective in promoting long-term abstinence from smoking and may reduce risk for relapse through attenuation of withdrawal symptoms and craving. Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies. Thirty smokers were randomly assigned to bupropion or placebo and interviewed using the Minnesota Nicotine Withdrawal Scale on two occasions: prior to starting medication and after 14 days on bupropion or placebo. The individual symptoms of craving, irritability, and anxiety were significantly reduced in the bupropion group, whereas no withdrawal symptoms were diminished in the placebo group. Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. In the DRD2-Taq1 A1/A1 and A1/A2 groups, no significant reduction was seen in any individual symptom of the nicotine withdrawal syndrome. These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor.

UR - http://www.scopus.com/inward/record.url?scp=9144252813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144252813&partnerID=8YFLogxK

U2 - 10.1080/14622200310001615295

DO - 10.1080/14622200310001615295

M3 - Article

C2 - 14668077

AN - SCOPUS:9144252813

VL - 5

SP - 935

EP - 942

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 6

ER -